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Abstract 
Solid tumours have oxygen gradients and areas of near and almost total anoxia. Hypoxia 
reduces sensitivity to 5-fluorouracil (5-FU)-chemotherapy for colorectal cancer (CRC). 
MicroRNAs (miRNAs) are hypoxia sensors and were altered consistently in six CRC cell 
lines (colon cancer: DLD-1, HCT116 and HT29; rectal cancer: HT55, SW837 and VACO4S) 
maintained in hypoxia (1% and 0.2% oxygen) compared to normoxia (20.9%). CRC cell lines 
also showed altered amino acid metabolism in hypoxia and hypoxia-responsive miRNAs 
were predicted to target genes in four metabolism pathways: beta-alanine; valine, leucine, 
iso-leucine; aminoacyl-tRNA; and alanine, aspartate, glutamate. MiR-210 was increased in 
hypoxic areas of CRC tissues and hypoxia-responsive miR-21 and miR-30d, but not miR-
210, were significantly increased in 5-FU resistant CRCs. Treatment with miR-21 and miR-
30d antagonists sensitised hypoxic CRC cells to 5-FU. Our data highlight the complexity and 
tumour heterogeneity caused by hypoxia. MiR-210 as a hypoxic biomarker, and the targeting 
of miR-21 and miR-30d and/or the amino-acid metabolism pathways may offer translational 
opportunities. 
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Introduction 
Recurrence of colorectal cancer (CRC) following surgery and chemotherapy occurs in almost 
50% of patients and is driven, in part, by the acquisition of resistance to chemo- and 
radiotherapy (1). Low oxygen tension (hypoxia) within the tumour microenvironment is a 
consistent feature of solid tumours. Hypoxia is associated with a poorer prognosis for many 
cancers, including breast (2), cervix (3), head and neck (4), and CRC (5). This is probably 
due hypoxic areas being more resistant to chemo- and radiotherapy (6,7). Understanding the 
relationship between the hypoxic microenvironment and how the tumour cells therein adapt 
to survive and proliferate is critical in developing better therapies that circumvent 
mechanisms of resistance.  
 
Hypoxia inducible factor (HIF-1α) is the key regulator of cellular response to hypoxia and 
can act as an experimental biomarker of hypoxia. Although a few reports have shown a 
correlation between HIF-1α and poor prognosis (8,9), accurately detecting hypoxia is 
challenging (10) due to tumour heterogeneity, the short half-life of the protein and technical 
issues associated with immuno-histochemical (IHC) detection in formalin-fixed paraffin-
embedded (FFPE) sections. Moreover, indirect assessment of hypoxia using endogenous 
markers such as HIF are inherently different from direct measures of oxygen partial pressure, 
which themselves present technical difficulties and shortcoming when assessing tumours in 
vivo or ex-vivo. Potentially any HIF-1α responsive protein could act as a surrogate marker of 
tumour hypoxia and most attention has focused on carbonic anhydrase 9 (CAIX). CAIX has 
been considered an endogenous marker of hypoxia and many solid tumors overexpress CAIX 
(11). The relationship between the expression of CAIX and patient outcome has been 
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investigated extensively (reviewed in 12), although expression of CAIX as a consequence of 
hypoxia is often implied rather than proven. 
 
MicroRNAs (miRNAs) are non-coding RNA molecules that regulate mRNAs (13-15). Their 
expression is altered in tumours compared to normal tissue and both oncogenic and tumour 
suppressive roles have been identified for them (16). In addition, miRNAs are differentially 
expressed and their biogenesis altered in the hypoxic regions of tumours (17-22). Hypoxia-
responsive miRNAs have been identified by comparing cancer cell lines maintained in 
hypoxia against controls sustained in normoxia. Furthermore, hypoxic signatures of miRNA 
expression are known for a number of tumour types including glioblastoma and bladder 
cancer (23,24). However, in vitro studies have often used only a few cancer-specific lines and 
corroborating in vivo data remains very limited. A larger-scale identification of miRNA 
expression under hypoxia in an extensive panel of CRC cell lines with supporting in vivo data 
is currently lacking. 
 
The hypoxamir-210 is consistently upregulated in hypoxia across a number of cancer types 
(25). Many targets of miR-210 regulate cell cycle, differentiation, apoptosis, translation, 
transcription, metabolism and migration (25). Using matched fresh frozen CRCs and control 
tissue, Qu and colleagues showed that miR-210 was frequently up-regulated in the cancer 
(26). Although the degree of hypoxia was not assessed in resected tissues, miR-210 
expression correlated significantly with large tumour size, lymph node metastasis, advanced 
clinical stage and poor prognosis (26). Experimental over-expression of miR-210 promoted 
migration and invasion in transwell experiments using the HT-29 and SW480 CRC lines in 
vitro (26). However, whether hypoxia modulated these responses was not investigated. 
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The chemotherapeutic drug 5-Fluorouracil (5-FU) has for decades been the standard first-line 
treatment for CRC (27). Although treatment options have broadened with the availability of 
therapies combined with 5-FU, tumour resistance remains a major challenge in the treatment 
of advanced CRC (28,29). The altered profile of miRNAs induced by 5-FU has been 
determined in CRC cell lines maintained in normoxia (30), but the role of hypoxia on miRNA 
modulation of chemosensitivity has not been investigated extensively. In particular, it is 
unclear whether expression of individual miRNAs is simply a consequence of hypoxia, or 
whether hypoxia-responsive miRNAs are of critical biological importance. For example, 
metabolic reprogramming is essential for cancer cell survival, with and without the additional 
stress of surviving exposure to chemotherapy drugs, in both normoxic and hypoxic 
environments. In the cancer cell, miRNAs regulate key metabolic transporters and enzymes 
(31), and so a role for hypoxia-responsive miRNAs is possible and requires investigation. 
 
Clearly, the identification of markers of hypoxia with clinical/biomarker utility and an 
understanding of their role in tumorigenesis would be welcomed. Moreover, a better 
understanding of the molecular events involved in tumour adaptation to hypoxia and its 
consequences with respect to treatment response will help to improve survival outcome for 
CRC patients. Whilst in vitro experimental studies commonly use oxygen tensions in the 
region of 0.8-1.0%, there is a paucity of data from studies that consider conditions of more 
severe hypoxia. Yet large gradients of oxygen tension, including areas of near anoxia (0.1% 
O2) and almost total anoxia have been recorded in tumours and in a spheroid model (32-36). 
 
Here, we investigated miRNA expression and metabolite profiles in a panel of six CRC cell 
lines under hypoxic (1%) and severe hypoxic (0.2%) conditions. Following validation, in situ 
hybridisation demonstrated the up-regulation of miRNAs in human CRC tumours. Hypoxia-
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responsive miRNAs were upregulated in 5-FU resistant CRC tumours and miRNA inhibition 
in vitro could sensitise CRC cells to 5-FU in hypoxia. Finally, our studies indicate that 
changes in the metabolic profile affected by hypoxia in the CRC cell line panel are associated 
with altered amino acid metabolism and may be linked with hypoxia-responsive miRNAs. 
 
Results 
miRNA array revealed hypoxia-responsive miRNAs in CRC cell lines 
miRNAs are key players in many cellular processes, including pathways that respond to 
changes in the cell microenvironment such as hypoxia. CRC cell lines are representative of 
the main subtypes of primary tumours at the genomic level and effective tools for 
investigating colorectal cancer biology (37). First, we aimed to identify miRNAs expressed 
commonly in three colon cancer cell lines (DLD-1, HCT116, HT29) and three rectal cancer 
cell lines (HT55, SW837, VACO4s) cultured for 48h in normoxic (20.9% oxygen) and two 
hypoxic tensions (1% and 0.2% oxygen). Following global miRNA expression profiling (see 
Material and Methods), log-transformed expression data of the six cell lines was subjected to 
partial least squares discriminant analysis (PLS-DA) modelling (see Materials and Methods, 
Supplementary Material, Table S1 and S2). Here, the analysis was supervised with regards to 
cell line and unsupervised in regards to oxygen tension. Unsurprisingly, there were clear 
differences between the six cell lines (Fig. 1A). However, PLS axis 6 showed an additional 
(and unsupervised) separation according to oxygen tension for 5 out of the 6 cell lines (Fig. 
1B). Even though the cell line is by far the greatest source of variance in the data, there is a 
miRNA signature of hypoxia once the effects of cell line have been allowed for. 
 
Given this, we used (univariate) linear models for each miRNA in turn against each cell line 
(treated as a categorical variable) and oxygen tension (treated as an ordinal variable). 41 
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miRNAs (2.2%, 41/1,896) were significantly (p<0.05) associated with oxygen tension (see 
Supplementary Material, Table S3). Fold change in expression between normoxia and both 
hypoxic tensions (20.9% versus 1% and 20.9% versus 0.2%) were calculated. Log 
transformed fold changes for the 41 altered miRNAs are ranked according to their PLS-DA 
loadings from the PLS axis 6 and illustrated in a heatmap (Fig. 1C). The most significantly 
altered miRNA across the six cell lines was miR-210, which accords with previous reports 
that miR-210 is consistently up-regulated following hypoxia in cancer cell lines (38). PLS-
DA loadings of axis 6 demonstrated high loading scores (see Supplementary Material, Fig. 
S1), also showing that this miRNA has a large impact on the separation of the miRNA data 
between the three oxygen conditions. 
 
Next, we chose a subset of 12/41 candidate miRNAs that were upregulated for validation 
(miR-19b; -106b; -141; -147; -1180; -21; -29a*; -210; -30d; -320a; -320b; 320c) based on 
previous reports linking the miRNA to hypoxia or therapy resistance and/or on statistical 
significance values, and the view that upregulated miRNAs rather than down regulated might 
have better utility as biomarkers (21, 38-43). Validation was performed by qRT-PCR on 
independently generated samples, which confirmed the marked increase in miR-210 under 
both hypoxic conditions (Fig. 2A-B). A further 12 miRNAs were confirmed as significantly 
altered under the hypoxic oxygen tensions as compared to normoxia; seven were significant 
for 20.9% versus 1% oxygen and five for 20.9% versus 0.2% oxygen, respectively (Fig. 2A-
C). These miRNAs were ranked according to their p-value calculated from the linear 
regression (Fig. 2D) and overall, the up-regulation of six miRNAs (miR-21, -210, -30d, -
320a,b, and c) was validated under both low oxygen tensions in CRC in vitro and miR-210 
again found to be the most significant.  
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A role for cellular metabolism in hypoxia in CRC cell lines  
The microenvironment in tumours, in particular hypoxia, is a key driver of changes in 
metabolic pathways that impact on cell survival and drug-resistance, and contribute to 
recurrence and metastasis. Using capillary electrophoresis-time of flight mass spectrometry 
(CE-TOFMS) we have identified changes in the metabolite expression profiles across the 
panel of six CRC cell lines under hypoxic conditions (1% and 0.2%) as compared to 
normoxia. A total of 92 significantly altered metabolites (p<0.05) were identified after linear 
modelling following fitting for cell line and oxygen tension (see Supplementary Material, 
Table S4). We observed a significant increase in lactate in cells confirming the hypoxic state 
of the cells (see Supplementary Material, Fig. S2). To allow broad pathway analysis, 
significantly altered metabolites were subjected to an over-representation analysis 
(MetaboAnalyst, www.metaboanalyst.com). This identified ten metabolic pathways that are 
enriched when cells are cultured under hypoxia (Fig. 3A). To investigate the potential role of 
hypoxia-responsive miRNAs from our previous analysis (Fig. 1C) in modulating these 
pathways, in silico target analysis was performed on all miRNAs detected by the array. 
Interestingly, hypoxia-responsive miRNAs are significantly predicted to target genes in four 
pathways: beta-Alanine (p<0.0001, Fig. 3B); valine, leucine, iso-leucine metabolism 
(p=0.002, Fig. 3C); aminoacyl-tRNA metabolism (p=0.027, Fig. 3D); and alanine, aspartate, 
glutamate metabolism (p=0.048, Fig. 3E). Genes targeted for each pathway by hypoxia-
responsive miRNAs are listed and ranked by their corresponding miRSVR score. These data 
indicate that hypoxia modulates amino-acid metabolism and that this modulation could 
involve hypoxia-responsive miRNAs. 
 
miR-210 is upregulated in CRC tissue and correlates positively with the hypoxia 
marker CAIX 
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To corroborate our in vitro hypoxia-responsive data, the expression of candidate miRNAs 
was tested in 13 human CRC samples. Normal and tumour regions were identified on H&E 
stained paraffin sections of CRC tumour tissue and then small RNAs (including miRNAs) 
were extracted from appropriate regions of corresponding serial sections. The hypoxia marker 
CAIX was used as a comparator by staining a serial section with CAIX and the extent of 
expression within the CRC tumour determined according to Korkeila et al (44). The 
expression of miR-210, miR-21 and miR-30d was assayed by qRT-PCR and correlation 
between the miRNA expression and CAIX staining within the tumour was determined. 
Spearman’s rank correlation demonstrated that the expression of miR-210 correlated 
positively to the expression of the hypoxia marker CAIX (Rho=0.67, p=0.01, Fig. 4A). By 
contrast, neither miR-21 nor miR-30d expression had any correlation to CAIX expression 
(miR-21, Rho=-0.019, p=0.95; miR-30d, Rho=0.069, p=0.823; Fig. 4B-C). 
 
To determine the localisation of miR-210 within the tumour tissue, in situ hybridisation was 
performed for miR-210 on sections available from eight of the 13 FFPE blocks and compared 
with any corresponding hypoxic regions in a serial section stained for CAIX. In all tumours, 
both CAIX and miR-210 were expressed in the epithelial cells of the gut crypts and their 
expression overlapped in the majority of the tumours (Fig. 4D-E). Our data provided in vivo 
confirmation of the correlation between miR-210 and hypoxia identified in the CRC cell line 
panel. 
 
Differential miRNA expression in 5-FU resistant CRC tumours 
5-FU is the standard first-line treatment for CRC. However, resistance, partly as a 
consequence of tumour hypoxia, remains a major challenge (27-29). Therefore, we 
investigated which miRNAs are altered in CRC tumours of patients that had undergone 
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adjuvant 5-FU treatment (n=11) and for whom survival data were available (responders, >5 
years survival post-surgery; non-responders, <5 years). Clinicopathological features of 
patients are given in Supplementary Material, Table S5. A total of 33 (4.1%, 33/800) 
significantly enriched miRNAs were identified by array profiling (see Materials and 
Methods) in tumours associated with non-response to 5-FU treatment (Fig. 5A, adjusted p-
value<0.05). miR-21 and four members of the miR-30 family (miR-30a,b,c, and d) showed 
the highest fold changes between the responders versus non-responders (Fig. 5B). 
Importantly, miR-210 was not amongst the significant miRNAs. A Spearman’s rank 
correlation analysis identified a significant negative correlation between the expression of 
both miR-21 (Rho=-0.6818; p=0.02, Fig. 5C) and miR-30d (Rho=-0.6182, p=0.0478, Fig. 
5D) to patient survival. 
 
miR-21 and miR-30d modulate 5-FU resistance in hypoxic DLD-1 cells 
Our data suggest a possible role for altered miRNA profiles in 5-FU resistant CRC tumours. 
Interestingly, miR-21 and miR-30d are two of only three miRNAs that are common across 
both the in vitro hypoxia and ex vivo CRC tissue arrays (Fig. 6A). 
The functional roles of miR-21 and miR-30d in 5-FU resistance under conditions of severe 
hypoxia (0.2%) were investigated in vitro in DLD-1 cells and contrasted with the hypoxamir 
miR-210. The rationale for selecting the DLD-1 cell lines for these experiments included the 
marked induction of the hypoxamir miR-210 in addition to miR-21 and 30d, which together 
had the highest fold change in hypoxic DLD-1 cells compared to the other cell lines (Fig. 
2C). DLD-1 cells were grown under two oxygen conditions (20.9% or 0.2%) and transfected 
with miRNA mimic/inhibitor or their appropriate control prior to 5-FU treatment (Fig. 6B). 
Cells were treated with various concentrations of 5-FU and from these experiments a dose 
(2mM) was selected that gives between 60 and 80% cell survival in 0.2% hypoxia (see 
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Supplementary Materials, Fig. S3). Under normoxic conditions, treatment with this dose 
resulted in an average cell survival of 42% and 40% for the Non-Targeting Control (NTC) 
mimic or inhibitor, respectively (green bars, Fig. 6C). Under 0.2% oxygen, cell survival 
increased to 80% and 89% following transfection with NTC mimic or inhibitor, respectively 
(red bars, Fig. 6C). Next, cells were transfected with the mimic or inhibitor of the three 
hypoxia-responsive miRNAs (miR-210, -21 and -30d) under normoxic and hypoxic 
conditions. Survival data for each miRNA was normalised to its appropriate NTC control. 
Under normoxic conditions, no change in cell survival was observed when cells were 
transfected with either the mimic or inhibitor of either miRNA (Fig. 6D). However, when 
cells were transfected with inhibitors for miR-21 or miR-30d under 0.2% oxygen a significant 
reduction in cell survival was observed compared to their NTC inhibitor control (miR-21 
inhibitor, p=0.0390; miR-30d inhibitor, p=0.0047; Fig. 6E). Taken together, these data 
demonstrated that down-regulation of miR-21 or miR-30d can sensitise DLD-1 cancer cells 
to 5-FU under hypoxic conditions. This indicates a functional role for miR-21 and miR-30d 
in the molecular events leading to 5-FU resistance in low oxygen conditions. 
 
DISCUSSION 
We have identified altered miRNA and metabolism profiles in a panel of CRC lines (three 
colon and three rectum) at two hypoxic oxygen tensions. Our data reveal that while there are 
differences between the cell lines, a set of miRNAs changes in response to hypoxia can be 
identified, once allowance has been made for the effects of the cell line. Significant 
differences were highlighted in the expression of miRNAs between the three oxygen 
conditions and six miRNAs (miR-21, -210, -30d, -320a, -320b, and -320c) were up-regulated 
consistently under both hypoxic conditions (1 and 0.2%) in vitro. We sought to confirm our 
data in tumour samples from patients to determine the link between 5-FU resistance, hypoxia 
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and miRNAs. The hypoxamiR-210 has a key role in cellular responses to low oxygen 
conditions in cancer cell lines and has been linked to clinico-pathological features in CRC 
including outcome (26,38). Our data confirmed the importance of miR-210 in hypoxic CRC 
cells in vitro, which we now link to hypoxia in vivo by demonstrating co-expression with 
CAIX, a known marker of hypoxia in CRC, as a comparator (12, 44). Both CAIX and miR-
210 were expressed in the epithelial cells of the gut crypts and their expression overlapped. 
This highlights the potential use of miR-210 as an in situ hypoxia biomarker for use in CRC 
FFPE tissue, which has been suggested by others linking expression to prognostic factors 
including metastasis in CRC (26); but this requires large scale trials for validation. Given the 
importance of hypoxia in chemotherapy resistance, a larger scale investigation is now 
warranted to determine whether increased in vivo miR-210 expression per se can be used to 
predict patient outcome. 
 
Resistance to 5-FU-based therapy poses a major challenge to clinical management. 
Therefore, we aimed to identify those miRNAs that are differentially expressed in CRC 
tumours that are either responsive or resistant to 5-FU-based therapy based on 5-year survival 
data. a change in the expression of a number of miRNAs in 5-FU resistant tumours relative to 
susceptible tumours was identified including the hypoxia-responsive miR-21 and miR-30d. 
Although numbers in our series was limited, we do corroborate the findings of others who 
reported that miR-21 was amongst the most strongly up-regulated miRNAs in 5-FU resistant 
CRC tumours and correlated significantly with reduced survival in patients with CRC and 
pathological response to 5-FU-based therapies in rectal cancer (45, 47). In addition to 
confirming results for miR-21, we have now shown for the first time, that miR-30d is also up-
regulated in 5-FU resistance CRC tumours and that this maybe associated with poor survival. 
The small sample set currently limits clinical utility and so our observational data requires 
13 
 
further validation in a larger cohort where account is taken of the degree of hypoxia within 
the tumour. Our finding that DLD-1 cells can be sensitised to 5-FU with anti-miR-30d under 
hypoxic conditions provides further impetus. 
 
Earlier studies showed that miR-21 over-expression reduced responsiveness to 5-FU based 
therapies by targeting mutS homolog (MSH)2, MSH6 and sprouty homolog (Spry)2 (47,48), 
and enhanced chemo-sensitivity in the HT-29 cell line to 5-FU (49). Both miR-30d and miR-
21 have been reported to be up-regulated in the 5-FU resistant CRC cell line KM12C (50). 
However, the role of hypoxia was not explored in these studies. We have shown that the CRC 
cell line DLD-1 can be sensitised to 5-FU with anti-miR-21 as well as anti-miR-30d under 
hypoxic conditions. Interestingly, miR-21 expression is increased in CRC cell lines exposed 
to 5-FU (51). A hypoxia-driven increase in miR-21/miR-30d expression could be a potential 
mechanism for acquired resistance to chemotherapy drugs such as 5-FU. 
 
Tumour cells are known to have a reprogrammed metabolism compared to normal cells, 
including specific features such as reliance on aerobic glycolysis (the Warburg effect) (52-
54). We observed a large number of metabolic changes in the same panel of six CRC cell 
lines under hypoxia, beyond the expected alterations in key metabolites such as lactate. 
Metabolic pathway overrepresentation analysis should arguably be considered an exploratory 
technique, rather than a means of determining exactly which pathways have been altered by a 
treatment. Nonetheless, we observed changes in a number of pathways involved in amino 
acid metabolism. In particular, the inclusion of the high-level “pathway” of aminoacyl-tRNA 
metabolism supports a hypothesis that overall changes in amino acid pools are probably 
driven by changes in protein synthesis rates controlled, in part, by hypoxia responsive 
miRNAs. These, in turn, may influence cell growth rates and response to drug treatment. In 
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support of this, Frezza and colleagues also reported altered amino acid profiles under hypoxia 
in a single CRC cell line HCT116 (55). Changes in amino acid concentrations have been 
reported previously in CRC tumour tissue compared to normal gut mucosa, suggesting a link 
between modulated amino acid metabolism and CRC (56). Hypoxia can increase the 
expression of amino acid transporters such as solute carrier family 7 members 5 and 11 via 
HIFs (57,58), to cope with the rise of non-aerobic energy demands. The latter was shown to 
occur as a consequence of chemotherapy as well as hypoxia (58). 
 
While miRNAs play complex roles in gene regulation using in silico analysis revealed a 
potential link between the hypoxia-responsive miRNAs and genes involved in amino acid 
metabolism. For example, dihydropropyrimidine dehydrogenase (DPYD), an enzyme active 
in amino acid metabolic pathways, including beta-Alanine metabolism, is targeted by 
hypoxia-responsive miRNAs miR-29a and miR-96. Interestingly, variants in DPYD are 
predictive of toxicity by 5-FU-based therapies in cancer (59). Also, miR-494 sensitises CRC 
cell line SW480 to 5-FU by targeting DPYD (60), suggesting a link between amino acid 
metabolism and drug resistance in CRC. Our investigation on a possible link between 
metabolism and hypoxia-responsive miRNAs has highlighted more complexity than has 
hitherto been considered. Further experimental investigation of the exact role of miRNAs and 
the link between them and altered metabolism in hypoxia is required. Furthermore, this will 
require confirmation in oxygen-deprived regions of tumour tissue. 
 
In summary, our work has demonstrated the complexities and multiple cellular consequences 
of hypoxia. It highlights the importance of interrogating a panel of cell lines and the 
challenge of integrating data across multiple platforms and between model systems including 
cell lines and tumour samples, with their inherent heterogeneity. As yet there is no definitive 
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answer as to whether all or only a few hypoxia responsive miRNAs have a role of biological 
significance in the oxygen-deprived microenvironment of the tumour. Many of these roles 
still need to be determined, but it seems likely that both scenarios are true. Nevertheless, our 
in vivo analyses confirmed miR-210 as a CRC hypoxamir, indicating its potential as a 
biomarker of hypoxia, and determined the localised expression of miR-21 in CRC, which 
suggested an important role for this miRNA in tumour cell maintenance and survival. 
Furthermore, we have identified important roles for miR-21 and miR-30d in 5-FU resistance 
in hypoxia. We have also highlighted the metabolic remodelling that occurs with increasing 
hypoxia. Further work is now necessary to investigate whether targeting miR-21 and miR-
30d and/or the amino-acid metabolism pathways in the hypoxic regions of tumours represent 
an appropriate therapeutic approach. 
 
Methods  
Ethics statement 
All methods were carried out in accordance with relevant guidelines and regulations. The 
Blizard Institute and local Ethics Committee (NRES Committee London; REC ref: 
13/LO/1271) approved experimental protocols that involved FFPE tissue samples from 
patients. Informed consent was obtained. 
 
Colorectal cancer cell lines and culture 
Three colon cancer (DLD-1, HCT116, HT29) and three rectal cancer (HT55, SW837, 
VACO4S) cell lines (37) were maintained in 5% CO2 humidified atmosphere containing 
Dulbecco’s Modified Eagles Medium (DMEM, Invitrogen, UK) supplemented with 10% 
Foetal bovine serum (FBS, Labtech, UK) and 10,000U/ml penicillin and 10,000µg/ml 
streptomycin (PenStrep, Sigma, UK). All cells were a kind gift from Professor Ian Tomlinson 
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(Wellcome Institute of Human Genetics, Oxford). Cells are regularly checked for known 
mutation status. For hypoxic experiments, cells were maintained at three different oxygen 
tensions (20.9%, 1% and 0.2%) controlled by an Invivo2 1000 Hypoxia Workstation 
(Ruskinn Life Sciences Ltd) for 48h. 
 
RNA extraction from cells and miRNA array 
Cell lines were incubated under three oxygen conditions for 48 hr. Extractions were 
performed with the miRNeasy kit (Qiagen, UK). RNA (2µg) was subjected to the LNA 7th 
generation Array (1,896 mature human miRNAs; total, 3,100 miRNA probes, miRBase v19, 
Exiqon, Denmark). Raw data was background corrected and normalised to mean plate 
intensity. 
 
RNA extraction from FFPE tissue and miRNA array 
All patients (n=11) had received 5-FU-chemotherapy and based on years survival post-
surgery were grouped into responders (survival >5 years) and non-responders (<5 years). A 
pathologist determined the tumour tissue area. Ten adjacent FFPE sections (10µm) from each 
CRC were used for miRNA extractions with the RecoverAll Total Nucleic Acid Isolation kit 
(Ambion, Applied Biosystems, USA). miRNA profiling was performed using the nCounter 
miRNA array (800 miRNAs, miRBase v12, Nanotechnologies, USA) because of its 
compatibility with FFPE tissue. Positive and negative control corrections were applied to the 
raw data, background was corrected and data was normalised using mean plate intensity. 
 
In situ hybridisation of miRNAs 
For in situ hybridisation of miRNAs, 13 CRC tumours were used. Sections (5µm) were cut in 
RNAse free water, deparaffinised, incubated with Proteinase-K (10 µg/ml) for 15min at 
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37°C, dehydrated and air-dried. Double-DIG-labelled miRNA probes (Exiqon, Denmark): 
miR-210 (40nM) and scrambled (60nM). Incubation was at 56°C for 2h with 25µL of probe 
followed by washing with saline-sodium citrate. Slides were incubated with blocking buffer 
for 15min, then with anti-DIG-Alkaline phophatase reagent (1:600, Exiqon, Denmark) at RT. 
Slides were washed with PBS-Tween and incubated with anti-AP substrate (NCT-BCIP, 
Roche, UK) for 2h at RT, washed in water before counterstaining with Nuclear Fast Red 
(Vector, UK). Slides were rinsed in running tap water for 10min, dehydrated, mounted with 
Eukkitt mounting medium (Sigma, UK) and then scanned using a Hamamatsu slide scanner. 
 
Quantitative real-time PCR 
10ng of RNA was used for reverse transcription with the microRNA Reverse Transcriptase 
kit (Applied Biosystems, UK). RT products were incubated with Taqman microRNA probe 
and Universal Mastermix (Applied Biosystems, UK) on a 7500 System RealTime PCR cycler 
(ABI) according to manufacturer’s protocol. Fold changes were calculated using the 2^-∆∆CT 
method normalised to the appropriate control. For CRC tissue, the geomean of miR-16 and 
let-7a were used as the endogenous control. For CRC cell lines RNU19b was used. 
 
Immunohistochemistry 
Sections (4µm) were de-waxed, hydrated and blocked in goat serum. Primary antibody for 
anti-CAIX (1:50, SantaCruz, UK) was used. Secondary antibody bound to HRP was 
incubated followed by washing, streptavidin-biotin and DAB incubation, and then 
counterstained with haematoxylin. Stomach tissue was used as positive control samples (44). 
Two observers, blinded to section details, assessed staining. 
 
miRNA transfection and 5-Fluoruracil (5-FU) treatments 
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DLD-1 cells were seeded in 96-well plates overnight then placed in either 20.9% or 0.2% 
oxygen. The next day, cells were transfected with 60nM miRNA mimic or 120nM miRNA 
inhibitor and their appropriate NTC (all from Qiagen UK). Cells were treated with 5-FU 
(2mM) the following day, for 48h, before harvesting. Cells were fixed with 3.7% PFA for 
15min and nuclei were stained with Hoechst 33342. Cells were imaged with the IN Cell 1000 
microscope (GE Healthcare, UK). Nuclei were counted using the IN Cell Developer Software 
v1.8. 
 
Metabolite analysis: CRC cell lines 
The levels of metabolites (fmol/cell) were determined by CE-TOFMS analysis. The six CRC 
cell lines were all cultured under the three oxygen conditions for 48h as described above. 
Cells were washed twice in 5% Mannitol (Wako, Japan) and harvested in methanol 
containing methionine sulfone, 2-morpholinoethanesulfonate and D-camphor-10-sulfonic 
acid, each at 25µM. Samples were flash frozen on dry ice and shipped to the Institute for 
Advanced Biosciences in Japan for CE-TOFMS as described previously (61, 62). 
 
Statistical analysis 
General statistics were performed using Prism (Graphpad) analysis software. Student’s t-tests 
and one-way ANOVA tests were used. A p-value of <0.05 was considered statistically 
significant. Experiments were performed in duplicate in three independent experiments, 
unless otherwise stated. 
 
For multivariate analysis, the supervised technique partial least squares discriminant analysis 
(PLS-DA) was used as this is particularly useful with highly multivariate datasets, but care 
must still be taken to avoid overfitting. One approach that can be very useful for experiments 
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with multiple factors is to model only one factor as supervised, which may also simplify the 
interpretation of the remaining, unsupervised factor (63). To accomplish this, fitting with 
respect to one variable was performed, and then the separation examined in another variable. 
Here, a supervised model to differentiate the six cell lines was fitted, and the miRNAs were 
examined for (unsupervised) separation with respect to oxygen tension. The loadings were 
then interrogated in order to identify potential miRNAs for further investigations. 
 
The multivariate analysis was complemented with univariate analyses. The relationship 
between miRNA expression (dependent variable) was modelled against the independent 
variables oxygen tension (numerical variable) + cell line (categorical variable) using multiple 
linear regression. This permitted the identification of miRNAs and metabolites that were 
significantly (p<0.05) associated with oxygen tension after allowance was made for the effect 
of cell line. 
 
The August 2010 release of predictive targets for each miRNA was obtained from (64) for 
good mirSVR scores of both conserved and non-conserved miRNA. Gene pathway 
information was obtained from www.miRWalk.com and the number of genes targeted with a 
mirSVR score <-1.25 by the significant miRNAs was calculated. To calculate the fold 
enrichment of each of these pathways with our significant miRNAs a permutation analysis 
was performed. We randomly sampled 1,000 different sets of miRNAs from the non-
significant list in our experiment and calculated the overlap for each pathway. These values 
were compared to our significant values and the fold enrichment and exact p-value were 
calculated. 
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Figure legends 
Figure 1. Altered miRNA expression profile under hypoxic conditions. Log-transformed 
fold change expression of significant miRNAs between normoxia (20.9%) and both low 
oxygen conditions (1% and 0.2%) in six CRC cell lines for 48h. (A) Data was subjected to 
PLS-DA, which was supervised according to cell line and unsupervised to oxygen tension. 
Observation of the first two axes (PLS 1 and PLS 2) demonstrated a clear separation of the 
miRNA data between the different cell lines, suggesting the main variation in the data is due 
to the differential expression of the miRNAs between the cell lines; further cell line 
differences were observed on additional PLS axes and are not shown here (6 axes were fitted 
on the basis of cross-validation). (B) A separation of the data according to oxygen tension 
was observed along PLS axis 6 in five of the six cell lines (excluding SW837). This model 
indicates an existence of differential expression of miRNA between cells maintained under 
the three different oxygen conditions. (C) miRNAs that are significantly altered under 
hypoxia were subsequently identified by linear regression multivariate analysis. A heatmap of 
log transformed fold changes between the different oxygen tensions normalised to 20.9% is 
shown. The miRNAs are ranked according to PLS-DA loadings. 
 
Figure 2. Validation of hypoxia-responsive miRNAs by qRT-PCR in six CRC cell lines. 
(A-B) Fold change expression of candidate miRNAs in normoxia (20.9%) and low oxygen 
tensions (1% and 0.2% oxygen) in six CRC cell lines combined. (C) Heatmap of fold change 
(log2) in miRNA expression between the three oxygen conditions normalised to 20.9% 
oxygen (n=3). (D) Multivariate analysis (linear regression model) identified a significant up-
regulation of 6 of the 12 miRNAs between in hypoxia. The heatmap is ranked according to p-
values obtained from the multivariate analysis. Asterisks indicate significantly altered 
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(p<0.05) miRNAs. Bars represent mean values with SEM calculated from three individual 
experiments. *p<0.05, **p<0.01 and ***p<0.001. 
 
Figure 3. Cellular metabolism altered under hypoxic conditions in CRC cell lines. 
Metabolite analysis via CE-TOFMS between six CRC cell lines maintained under normoxic 
(20.9%) and low oxygen conditions (1% and 0.2%). Over-representation analysis of 
significantly altered metabolites was performed using MetaboAnalyst. (A) Ten significant 
pathways associated with altered metabolites under hypoxic conditions. (B-E) In silico 
analysis of miRNA target prediction of genes involved in the ten pathways. Four pathways 
showed a significant association between hypoxia-responsive miRNAs. Genes with a 
miRSVR score lower than -1.25 are listed. 
 
Figure 4. In situ expression of miR-210 positively correlates to hypoxia marker CAIX in 
CRC tissue. (A-C) Scatter plots of miR-210, miR-21 and miR-30d expression (1/2-∆CT) 
assessed by qRT-PCR and percentage of CAIX-positive staining within the tumour (n=13). 
Correlation efficiency calculated with Spearman’s Rank analysis showed a significant 
positive correlation between miR-210 and CAIX expression CRC tumours (D-E) IHC of 
CAIX and in situ hybridisation of miR-210 performed on serial sections of FFPE blocks of 
CRC tumours (n=8). Staining of miR-210 was observed in the epithelial cells along the crypts 
and overlapped with CAIX staining within these cells. 
 
Figure 5. miRNA expression profiling in 5FU resistant CRC tumours and modulation of 
resistance in hypoxic DLD-1 cells. Eleven CRC tumours treated with 5-FU treatment (six 
non-responders, five responders) were subjected to miRNA profiling. (A) Heatmap of 
significant altered miRNAs (p<0.05, Benjamini-Hochberg adjusted). Corrected p-values are 
31 
 
shown. (B) Fold change in expression of miRNAs significantly altered between each group. 
(C-D) Correlation between patient survival and expression of miR-21 or miR-30d. 
Spearman’s rank analysis indicated a significant correlation between each miRNA and 
patient survival. 
 
Figure 6. MiR-30d modulates 5-FU resistance in hypoxic DLD-1 cells. (A) Venn Diagram 
of common miRNAs that are dysregulated in both arrays (in vivo hypoxia array and ex vivo 
CRC tissue array). (B) DLD-1 cells were transfected with miRNA mimic and inhibitors under 
normoxic and hypoxic conditions. Experimental timeline of the experiments is shown. (C) 
Cell survival following treatment with 2 mM 5-FU and vehicle (DMSO). Data normalised to 
untreated cells. (D-E) Graph represents fold change in survival following treatment with 5-
FU and vehicle. Data normalised to vehicle and then to its transfection control (NTC) 
Inhibition of miR-30d under hypoxic conditions resulted in a significant reduction in 
resistance to 5-FU. Bars represent mean values with SEM calculated from three individual 
experiments. *p<0.05, **p<0.01 
 
List of abbreviations used: carbonic anhydrase 9, CAIX; capillary electrophoresis time of 
flight mass spectrometry, CE-TOF/MS; colorectal cancer, CRC; dihydropropyrimidine 
dehydrogenase, DPYD; formalin-fixed paraffin-embedded, FFPE; hypoxia inducible factor-1 
alpha, HIF-1α; immuno-histochemical, IHC; microRNAs, miRNAs; microRNA support 
vector regression, miRSVR; mutS homolog, MSH; Non-Targeting Control, NTC; partial least 
squares discriminant analysis, PLS-DA; saline-sodium citrate, SSC; sprouty homolog, SPRY; 
5-fluorouracil, 5-FU. 
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